Treatment for low‐grade and high‐grade endometrial carcinoma after recurrence/relapse before the molecular targeted therapy era: A retrospective, propensity score‐matched cohort study
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16197 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Masao Okadome und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Service, NHO Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Recurrence, Local, Propensity Score. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Aim
To compare the prognosis of low‐grade endometrial carcinoma (LG‐EC) with that of high‐grade endometrial carcinoma (HG‐EC) after first recurrence/relapse before the molecular targeted therapy era.
Methods
Recurrent/relapsed endometrial cancer was diagnosed in 155 women at our hospital between January 26, 1999 and February 26, 2019. Fifty of these women received paclitaxel–carboplatin, two received doxorubicin–cisplatin, and one received docetaxel–carboplatin as postoperative chemotherapy. Two women who did not receive postoperative chemotherapy received paclitaxel–carboplatin for their first recurrence/relapse. The prognosis in these 55 women was retrospectively investigated using propensity score matching.
Results
Twenty‐five women had LG‐EC and 30 had HG‐EC. Cox proportional hazards analysis identified response to chemotherapy for the first recurrence/relapse to be a statistically significant determinant of progression‐free survival and HG‐EC to be a significant determinant of overall survival. After propensity score matching, median overall survival was better in women with LG‐EC than in those with HG‐EC (82 months [95% CI 27–not reached] vs. 31 months [95% CI 2–47], p = 0.0127). Three women survived for at least 10 years without recurrence after completion of treatment. The interval between postoperative chemotherapy and first recurrence was more than 6 months. The recurrences resolved after multimodal treatment or aggressive chemotherapy followed by 5–12 cycles of chemotherapy other than paclitaxel–carboplatin if received postoperatively.
Conclusions
The prognosis was poorer in patients with recurrent/relapsed HG‐EC than in those with recurrent/relapsed LG‐EC before the molecular targeted therapy era. There were no long‐term recurrence‐free survivors after repeat paclitaxel–carboplatin chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecology Service, NHO Kyushu Cancer Center, Fukuoka, Japan.
- Department of Gynecology, Kyushu University Beppu Hospital, Beppu, Japan.
ORCID-Profile: Ai Nio
Zitieren
APA
Okadome, M., Sonoda, K., Nagayama, R., Saito, T., Shimamoto, K., Nio, A., Yoshida, Y., Tsubomi, A., Yamaguchi, S., & Ariyoshi, K. (2025). Treatment for low‐grade and high‐grade endometrial carcinoma after recurrence/relapse before the molecular targeted therapy era: A retrospective, propensity score‐matched cohort study. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16197
Vancouver
Okadome M, Sonoda K, Nagayama R, Saito T, Shimamoto K, Nio A, et al. Treatment for low‐grade and high‐grade endometrial carcinoma after recurrence/relapse before the molecular targeted therapy era: A retrospective, propensity score‐matched cohort study. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16197
BibTeX
@article{Okadome2025,
author = {Okadome, Masao and Sonoda, Kenzo and Nagayama, Rina and Saito, Toshiaki and Shimamoto, Kumi and Nio, Ai and Yoshida, Yu and Tsubomi, Ayano and Yamaguchi, Shinichiro and Ariyoshi, Kazuya},
title = {Treatment for low‐grade and high‐grade endometrial carcinoma after recurrence/relapse before the molecular targeted therapy era: A retrospective, propensity score‐matched cohort study},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16197}
}
EUVIMED